Clinical Trial Update: GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial of GDC-0941 (pictilisib) with cisplatin for androgen receptor-negative triple-negative metastatic breast cancer was terminated, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor Negative Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• pictilisib (GDC-0941) (pictilisib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-06-27